PARP inhibition in prostate cancer. Issue 5 (28th October 2020)

• Record Type: Journal Article
• Authors: Nientiedt, Cathleen; Duensing, Anette; Zschäbitz, Stefanie; Jäger, Dirk; Hohenfellner, Markus; Stenzinger, Albrecht; Duensing, Stefan
• Other Names: Stenzinger Albrecht guestEditor.; Gonzalez David guestEditor.
• Is Part Of: Genes, chromosomes & cancer. Volume 60:Issue 5(2021)
• Page Start: 344
• Page End: 351
• Publication Date: 2020-10-28
• Subjects: DNA damage repair genes -- PARP inhibition -- prostate cancer; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22903
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Defects in DNA damage repair genes are more common in prostate cancer than previously thought. These alterations provide an opportunity for precision oncology approaches and a number of studies have now shown that PARP inhibitors can have significant antitumor activity in men with DNA damage repair‐deficient metastatic castration‐resistant prostate cancer. This review summarizes the key clinical trials related to the use of PARP inhibitors in prostate cancer. Besides clinical outcomes, toxicity, and PARP inhibitor resistance, the role of different DNA repair genes in the response to PARP inhibition will be discussed.